Iron supplementation: Encourage rest to prevent postural hypotension, oxygenation to make oxygen saturation ≥90% if necessary, eating iron-rich food, strengthening nutrition, and inputting iron supplements, such as iron dextrose, if necessary. Although serum iron and serum ferritin are normal in most patients, there are iron metabolism disorders, mainly iron utilization disorder. At the same time of iron supplementation, the application of recombinant human erythropoietin ( rHuEPO ) treatment, that is, can lift the iron utilization obstacles, so as to effectively consume the body’s iron stores. Blood transfusion: anemia in tumor patients is mostly caused by chronic onset and bone marrow hypoplasia, there is no indication for blood transfusion when Hgb 100 g/L or above, when Hgb<85 g/L, it should be combined with the patient's clinical manifestations, such as extreme fatigue, dizziness and headache, tachycardia, hypotension, and cardiac ischemia, then transfusion of RBCs can be considered, when Hgb<70 g/L, and the blood volume is normal, transfusion of RBCs can be considered, only tumor patients with active hemorrhage can be treated with recombinant human erythropoietin (rHuEPO). If the tumor patient has active bleeding and needs to replenish blood volume and red blood cells at the same time, whole blood transfusion should be considered.